<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018664</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 1008910 (TR08)</org_study_id>
    <nct_id>NCT04018664</nct_id>
  </id_info>
  <brief_title>Oral Abuse Potential Study of Nalbuphine</brief_title>
  <official_title>A Study to Evaluate the Oral Abuse Potential of Nalbuphine Solution and Extended-Release Intact Tablets in Non-Dependent, Recreational Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trevi Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid
      drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no
      active drug ingredients). The amount of nalbuphine levels in the blood will also be measured
      and the safety of the study drugs will be evaluated.

      This study has 2 parts: Part A and Part B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a single-dose, randomized, double-blind, active- and placebo-controlled,
      double dummy, 2-part, 7-way crossover study to determine the abuse potential of orally
      administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone
      solution and placebo, in non-dependent, recreational opioid users. The study will be
      conducted in a single clinical research unit (CRU).

      The purpose of Part A is to find the appropriate doses (a low, intermediate, and high dose)
      of nalbuphine solution to use in Part B. Part A of the study has two visits to the research
      clinic: a screening visit and dose selection visit. The visits will involve a 2-night stay (3
      days total) in the research clinic.

      In the Main Study Treatment Phase in Part B, the total estimated duration between each dose
      of study drug is approximately up to 7 days, of which the subject will spend 3 days/2 nights
      in the research clinic and approximately up to 4 days at home.

      The primary objective of the Main Study is to evaluate the abuse potential of orally
      administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone
      solution (the active comparator) and placebo in non-dependent, recreational opioid users.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Actual">June 2, 2020</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-dose, randomized, double-blind, active- and placebo-controlled, double-dummy, 2-part, 7-way crossover study.
Part A: Dose selection phase Part B: Treatment Periods 1-7</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>For each dosing cohort, an unblinded statistician, not otherwise involved in the study, will prepare a list of subject randomization numbers. These randomization numbers will be used to prepare individual subject doses. Sealed qualification code break envelopes will be available for each subject in case of emergency.
Upon completion of each cohort of subjects, the randomization codes for the completed subjects will be unblinded by the CRU pharmacy. After unblinding, the safety data will be reviewed to determine if dosing can proceed for the next planned dosing cohort,</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint for the Main Study is the peak (maximum) effect (Emax) for Drug Liking (&quot;at this moment&quot;), assessed on a bipolar, 0 to 100 point visual analog scale (VAS)</measure>
    <time_frame>19 weeks</time_frame>
    <description>The primary objective of the Main Study is to evaluate the abuse potential of orally administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone solution (the active comparator) and placebo in non-dependent, recreational opioid users</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking on the Visual Analog Scale(VAS) (Emax and peak minimum effect [Emin])solution and nalbuphine ER intact tablets</measure>
    <time_frame>19 weeks</time_frame>
    <description>To assess the cognitive and psychomotor effects of orally administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone solution and placebo in non-dependent, recreational opioid users</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again Visual Analog Scale (VAS) (Emax)</measure>
    <time_frame>19 weeks</time_frame>
    <description>To assess the safety and tolerability of orally-administered nalbuphine solution and nalbuphine ER tablets relative to hydromorphone solution and placebo in non-dependent, recreational opioid users.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Identification of an Maximum Safe Dose (MSD) of nalbuphine administered as nalbuphine oral solution</measure>
    <time_frame>4.5 weeks</time_frame>
    <description>To assess the safety and tolerability of various doses of orally-administered nalbuphine solution and determine the maximum safe dose (MSD) in non-dependent, recreational opioid users.</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Nalbuphine</condition>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment A: Placebo
150 mL flavored beverage +
1 × nalbuphine matching placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B: Hydromorphone HCL 8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B: Hydromorphone HCl 8 mg solution
4 mL × 2 mg/mL hydromorphone HCl + 146 mL flavored beverage +
1 × nalbuphine matching placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Hydromorphone HCL 16mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment C: Hydromorphone HCl 16 mg solution
8 mL × 2 mg/mL hydromorphone HCl + 142 mL flavored beverage +
1 × nalbuphine matching placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Nalbuphine HCL low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment D: Nalbuphine HCl low dose solution
Low dose nalbuphine HCl solution + TBD mL flavored beverage +
1 × nalbuphine matching placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: Nalbuphine HCL intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment E: Nalbuphine HCl intermediate dose solution
Intermediate dose nalbuphine HCl solution + TBD mL flavored beverage +
1 × nalbuphine matching placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F: Nalbuphine HCL High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment F: Nalbuphine HCl high dose solution
High dose nalbuphine HCl solution + TBD mL flavored beverage +
1 × nalbuphine matching placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment G: NAL ER 162 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment G: Nalbuphine 162 mg ER intact tablet
150 mL flavored beverage +
1 × 162 mg nalbuphine ER tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine 162 Mg ER</intervention_name>
    <description>Treatment G</description>
    <arm_group_label>Treatment G: NAL ER 162 mg tablet</arm_group_label>
    <other_name>NAL ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine HCl solution</intervention_name>
    <description>Treatment Arm D: given at a low dose Treatment Arm E; given at an intermediate dose Treatment Arm F: given at a high dosing</description>
    <arm_group_label>Treatment D: Nalbuphine HCL low dose</arm_group_label>
    <arm_group_label>Treatment E: Nalbuphine HCL intermediate dose</arm_group_label>
    <arm_group_label>Treatment F: Nalbuphine HCL High dose</arm_group_label>
    <other_name>Nubain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone HCl 8 mg</intervention_name>
    <description>Treatment Arm B: 8 mg Solution</description>
    <arm_group_label>Treatment Arm B: Hydromorphone HCL 8 mg</arm_group_label>
    <other_name>Hymorphan</other_name>
    <other_name>Tubex</other_name>
    <other_name>Palladon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone HCl 16 Mg</intervention_name>
    <description>Treatment Arm C: 16 Mg solution</description>
    <arm_group_label>Treatment C: Hydromorphone HCL 16mg</arm_group_label>
    <other_name>Tubex</other_name>
    <other_name>Palladon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Treatment Arm A</description>
    <arm_group_label>Treatment Arm A: Placebo</arm_group_label>
    <arm_group_label>Treatment Arm B: Hydromorphone HCL 8 mg</arm_group_label>
    <arm_group_label>Treatment C: Hydromorphone HCL 16mg</arm_group_label>
    <arm_group_label>Treatment D: Nalbuphine HCL low dose</arm_group_label>
    <arm_group_label>Treatment E: Nalbuphine HCL intermediate dose</arm_group_label>
    <arm_group_label>Treatment F: Nalbuphine HCL High dose</arm_group_label>
    <arm_group_label>Treatment G: NAL ER 162 mg tablet</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects 18 to 55 years of age

          -  Current opioid users who have used opioids for recreational (non-therapeutic) purposes

        Exclusion Criteria:

          -  Self-reported substance or alcohol dependence (excluding nicotine and caffeine)

          -  Heavy smoker (≥ 20 cigarettes per day) and/or who is unable to abstain from smoking
             for at least 8 hours during the in clinic periods.

          -  History or presence of clinically significant abnormality as assessed by physical
             examination, medical history, ECGs, vital signs, or laboratory values.

          -  History or presence of any clinically significant illness

          -  History of major mental illness that may affect the ability of the subject to
             participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Sciascia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trevi Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>001</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nalbuphine</keyword>
  <keyword>abuse potential</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

